Skip to main content

Table 13 Summary of findings table for treatment with erenumab 70 mg monthly subcutaneous injection compared with no treatment for prevention of chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Outcomes Anticipated absolute effects*(95% CI) Relative effect(95% CI) № of participants (studies) Certainty of the evidence(GRADE) Comments
Risk with placebo Risk with erenumab
Reduction of monthly migraine days follow up: 3 months The mean reduction of monthly migraine days was − 4.2 days The mean reduction of monthly migraine days in the intervention group was 2.5 days fewer (3.5 lower to 1.4 fewer) – 469(1 RCT) ⨁⨁⨁◯MEDIUMa Treatment with Erenumab 70 mg reduces monthly migraine days slightly compared to placebo.
Reduction of monthly acute treatment daysfollow up: 3 months The mean reduction of monthly acute treatment days was −1.6 days The mean reduction of monthly acute treatment days in the intervention group was 1.9 days fewer (2.6 fewer to 1.1 fewer) – 469(1 RCT) ⨁⨁⨁◯MEDIUMa Treatment with Erenumab 70 mg reduces monthly acute treatment days slightly compared to placebo.
At least 50% reduction of monthly migraine days follow up: 3 months 235 per 1000 399 per 1000(303 to 525) RR 1.6985 (1.2908 to 2.2349) 469(1 RCT) ⨁⨁⨁◯MEDIUMa Treatment with Erenumab 70 mg results in at least 50% reduction of monthly migraine days compared to placebo.
Serious adverse events follow up: 3 months 25 per 1000 31 per 1000(11 to 92) RR 1.2722(0.4340 to 3.7268) 471(1 RCT) ⨁⨁⨁◯MEDIUMa Treatment with Erenumab 70 mg results in a small unimportant increase of serious adverse event occurrence compared to placebo.
Mortalityfollow up: 3 months 0 per 1000 0 per 1000(0 to 0) not estimable 471(1 RCT)   No deaths were observed with treatment with Erenumab 70 mg or placebo
  1. CI: Confidence interval; RR: Risk ratio; RCT: randomized controlled trial; aDowngraded once due to imprecision: phase II study
  2. GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us

\